全球癌症基因治療市場規模和預測:按類型、最終用途和地區分析,2022-2029 年
市場調查報告書
商品編碼
1215310

全球癌症基因治療市場規模和預測:按類型、最終用途和地區分析,2022-2029 年

Global Cancer Gene Therapy Market Size study & Forecast, by Type, by End Use and Regional Analysis, 2022-2029

出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格

2021 年全球癌症基因治療市場價值約為 16.8 億美元,預計在 2022-2029 年預測期內將以超過 19.99% 的健康增長率增長。

癌症基因療法是一種新的治療方法,通過將新基因引入癌細胞和附近組織來幫助殺死或減緩癌症的生長。 由於該療法的靈活性以及在臨床試驗中使用多種基因和載體取得了良好的效果,作為一種治療人類疾病的新方法而備受關注。 蓬勃發展的醫藥行業、激增的抗癌新藥需求以及政府加大扶持力度是推動全球市場需求的關鍵因素,是一個因素。

全球癌症發病率上升是市場增長的主要驅動力。 據美國國家癌症研究所估計,2018 年癌症患者人數為 1810 萬人,預計到 2040 年將達到 2950 萬人。 因此,癌症患病率的增加推動了對廣泛的診斷和治療選擇的需求,從而推動了癌症基因治療市場的增長。 此外,在癌症基因治療方面不斷提高的技術進步和不斷擴大的研發投資為未來幾年的市場增長創造了有利可圖的機會。 然而,與基因治療相關的高成本和不良免疫反應阻礙了整個 2022-2029 年預測期內的市場增長。

全球癌症基因治療市場研究考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於成熟的市場參與者的存在以及對該地區醫療設施投資的增加,北美在收入方面佔據了市場主導地位。 另一方面,預計歐洲將在預測期內以最高複合年增長率增長。 政府機構增加對新療法的研究經費以及對新療法的需求增加等因素正在推動預測期內的市場增長。

本報告中包含的主要市場參與者是:

  • Abeona Therapeutics Inc.
  • Asclepius Biopharmaceutical Inc.
  • 藍鳥生物公司
  • 葛蘭素史克公司
  • Introgen Therapeutics Inc.
  • 默克公司
  • 生物取消墨水
  • 提升生物
  • Genelux 有限公司
  • Oncogenex Pharmaceuticals Inc.
市場的

近期發展

  • 2022 年 1 月,Ori Biotech Ltd. 完成了超過 1 億美元的 B 輪融資,幫助推出其創新細胞和基因治療製造平台的關鍵人員宣布,該平台將用於擴大
  • 2021 年 6 月,衛材與百時美施貴寶達成合作協議,共同開發 MORAb-202 並將其商業化,MORAb-202 是衛材用於晚期實體瘤的 ADC。

研究範圍:全球癌症基因治療市場

  • 歷史數據:2019-2020-2021
  • 基本估算年份:2021 年
  • 預測期間:2022-2029
  • 報告範圍盈利預測、公司排名、競爭格局、增長因素、趨勢等。
  • 涵蓋的細分市場類型、最終用途、地區
  • 區域覆蓋範圍北美;歐洲;亞太地區;拉丁美洲;世界其他地區
  • 定制範圍 報告定制是免費的(八小時分析師時間)。 添加/更改國家、地區、細分範圍*。

這項研究的目的是定義近年來各個細分市場和國家/地區的市場規模,並預測它們在未來幾年的價值。 本報告旨在捕捉被調查國家行業的定性和定量方面的情況。

它還提供了關鍵方面的詳細信息,例如決定市場未來增長的驅動因素和挑戰。 此外,它還包含供利益相關者投資的微觀市場潛在機會,以及對主要參與者的競爭格局和產品供應的深入分析。

按類型

  • 溶瘤生物療法
  • 基因轉移免疫療法
  • 基因轉移

由最終用戶

  • 研究所
  • 生物製藥公司
  • 診斷中心
  • 其他

按地區

  • 北美
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 意大利
  • 淨資產收益率
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 韓國
  • 下包
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 世界其他地區

內容

第 1 章執行摘要

  • 市場概況
  • 2019-2029 年各細分市場的全球市場估計和預測
    • 癌症基因治療市場:按地區劃分,2019-2029 年
    • 癌症基因治療市場:按類型分類,2019-2029
    • 癌症基因治療市場,按最終用途分類,2019-2029 年
  • 主要趨勢
  • 調查方法
  • 調查先決條件

第 2 章癌症基因治療的全球市場定義和範圍

  • 調查的目的
  • 市場定義和範圍
    • 調查範圍
    • 工業發展
  • 調查年份
  • 貨幣兌換率

第3章全球癌症基因治療市場動態

  • 癌症基因治療市場影響分析(2019-2029)
    • 市場驅動力
      • 抗癌新藥需求激增
      • 全球癌症發病率上升
    • 市場挑戰
      • 基因治療很昂貴
      • 不需要的免疫反應
    • 市場機會
      • 癌症基因治療技術進步的增加
      • 增加研發投資

第 4 章全球癌症基因治療市場行業分析

  • 波特 5 力模型
    • 供應商的議價能力
    • 買家的議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係
  • 波特 5 力模型的未來方法 (2019-2029)
  • 害蟲分析
    • 政治
    • 經濟的
    • 社交
    • 技術
  • 投資招聘模式
  • 分析師的結論和建議
  • 頂級投資機會
  • 關鍵成功策略

第 5 章風險評估 COVID-19 影響

  • 評估 COVID-19 對行業的總體影響
  • COVID-19 之前和 COVID-19 之後的市場情景

第 6 章全球癌症基因治療市場,按類型

  • 市場概況
  • 全球癌症基因治療市場:按類型劃分的表現 - 潛力分析
  • 2019-2029 年全球癌症基因治療市場、按類型估計和預測
  • 癌症基因治療市場,細分分析
    • 溶瘤生物療法
    • 基因引導的免疫療法
    • 基因轉移

第 7 章:全球癌症基因治療市場,按最終用戶分類

  • 市場概況
  • 全球癌症基因治療市場:按最終用途分類的結果 - 潛力分析
  • 2019-2029 年世界癌症基因治療市場,按最終用途估算和預測
  • 癌症基因治療市場,細分分析
    • 研究機構
    • 生物製藥公司
    • 診斷中心
    • 其他

第 8 章全球癌症基因治療市場:區域分析

  • 癌症基因治療市場:按地區劃分的市場概況
  • 北美
    • 美國
      • 按類型估算和預測,2019-2029 年
      • 2019-2029 年按最終用途估算和預測
    • 加拿大
  • 歐洲癌症基因治療市場概況
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 意大利
    • 其他歐洲地區
  • 亞太地區癌症基因治療市場概況
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 拉丁美洲癌症基因治療市場概況
    • 巴西
    • 墨西哥
  • 世界其他地區

第 9 章衝突信息

  • 頂級市場策略
  • 公司簡介
    • Abeona Therapeutics Inc.
      • 主要信息
      • 概覽
      • 財務信息(取決於數據可用性)
      • 產品概述
      • 近期趨勢
    • Asklepios BioPharmaceutical Inc.
    • Bluebird bio Inc.
    • GlaxoSmithKlineInc.
    • Introgen TherapeuticsInc.
    • MerckKGaA
    • BioCancell Inc.
    • Elevate BioInc.
    • Genelux Corporation
    • OncoGenex Pharmaceuticals Inc.

第 10 章研究過程

  • 研究過程
    • 數據挖掘
    • 分析
    • 市場評估
    • 驗證
    • 出版
  • 調查屬性
  • 調查先決條件

Global Cancer Gene Therapy Market is valued at approximately USD 1.68 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 19.99% over the forecast period 2022-2029. Cancer gene therapy is a new treatment modality that assists in the introduction of new genes into a cancerous cell or the nearby tissue that leads to cell death or slows the growth of cancer. This treatment technique is flexible and a variety of genes and vectors are being utilized in clinical trials that present positive results, which is gaining huge popularity as a novel method for treating human ailments. The flourishing development of the pharmaceutical industry, surging demand for novel cancer therapeutics, and rising government support are the primary factors that are fostering market demand across the globe.

The rising incidences of cancer globally are a key driving factor for market growth. According to National Cancer Institute, in 2018, the number of cancer patients is estimated to account for 18.1 million, which is projected to reach 29.5 million patients by the year 2040. Accordingly, the growing prevalence of cancer is fueling the demand for wide range of diagnosis and treatment alternatives, which, in turn, accelerates the growth of the Cancer Gene Therapy Market. Moreover, the increasing technological advancements in cancer gene therapy, as well as growing R&D investments, are creating lucrative opportunities for market growth in the foreseen years. However, the high cost associated with gene therapy and unwanted immune responses is hindering market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Cancer Gene Therapy Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the presence of well-established market players and increasing investment in healthcare facilities in the region. Whereas, Europe is expected to grow at the highest CAGR during the forecast period. Factors such as rising research funding for novel therapeutics by government bodies, as well as growing demand for novel therapeutics are burgeoning the market growth in the forecasting years.

Major market players included in this report are:

  • Abeona Therapeutics Inc.
  • Asklepios BioPharmaceutical Inc.
  • Bluebird bio Inc.
  • GlaxoSmithKlineInc.
  • Introgen TherapeuticsInc.
  • MerckKGaA
  • BioCancell Inc.
  • Elevate Bio Inc.
  • Genelux Corporation
  • OncoGenex Pharmaceuticals Inc.

Recent Developments in the Market:

  • In January 2022, Ori Biotech Ltd. publicized that the company has achieved above USD 100 million in funding in a Series B funding round, which is planned to use for the expansion of key personnel to support the launch of its innovative cell and gene therapy manufacturing platform.
  • In June 2021, Eisai and Bristol Myers Squibb entered collaborative agreement to form and marketing of MORAb-202, Eisai's ADC for advanced solid tumors.

Report Scope:Global Cancer Gene Therapy Market

  • Historical Data: 2019-2020-2021
  • Base Year for Estimation: 2021
  • Forecast period: 2022-2029
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Type, End Use, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
  • Customization Scope: Free report customization (equivalent to up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define the market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study.

The report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

  • Oncolytic Virotherapy
  • Gene Induced Immunotherapy
  • Gene Transfer

By End Use:

  • Research Institutes
  • Biopharmaceutical Companies
  • Diagnostic Centers
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Rest of the World

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
    • 1.2.1. Cancer Gene Therapy Market, by Region, 2019-2029 (USD Billion)
    • 1.2.2. Cancer Gene Therapy Market, by Type, 2019-2029 (USD Billion)
    • 1.2.3. Cancer Gene Therapy Market, by End Use, 2019-2029 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Cancer Gene Therapy Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Cancer Gene Therapy Market Dynamics

  • 3.1. Cancer Gene Therapy Market Impact Analysis (2019-2029)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Surging demand for novel cancer therapeutics
      • 3.1.1.2. Rising incidences of cancer globally
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost is associated with gene therapy
      • 3.1.2.2. Unwanted immune responses
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing technological advancements in cancer gene therapy
      • 3.1.3.2. Growing R&D investments

Chapter 4. Global Cancer Gene Therapy Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
  • 4.4. Investment Adoption Model
  • 4.5. Analyst Recommendation & Conclusion
  • 4.6. Top investment opportunity
  • 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

  • 5.1. Assessment of the overall impact of COVID-19 on the industry
  • 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Cancer Gene Therapy Market, by Type

  • 6.1. Market Snapshot
  • 6.2. Global Cancer Gene Therapy Market by Type, Performance - Potential Analysis
  • 6.3. Global Cancer Gene Therapy Market Estimates & Forecasts by Type 2019-2029 (USD Billion)
  • 6.4. Cancer Gene Therapy Market, Sub Segment Analysis
    • 6.4.1. Oncolytic Virotherapy
    • 6.4.2. Gene Induced Immunotherapy
    • 6.4.3. Gene Transfer

Chapter 7. Global Cancer Gene Therapy Market, by End Use

  • 7.1. Market Snapshot
  • 7.2. Global Cancer Gene Therapy Market by End Use, Performance - Potential Analysis
  • 7.3. Global Cancer Gene Therapy Market Estimates & Forecasts by End Use 2019-2029 (USD Billion)
  • 7.4. Cancer Gene Therapy Market, Sub Segment Analysis
    • 7.4.1. Research Institutes
    • 7.4.2. Biopharmaceutical Companies
    • 7.4.3. Diagnostic Centers
    • 7.4.4. Others

Chapter 8. Global Cancer Gene Therapy Market, Regional Analysis

  • 8.1. Cancer Gene Therapy Market, Regional Market Snapshot
  • 8.2. North America Cancer Gene Therapy Market
    • 8.2.1. U.S. Cancer Gene Therapy Market
      • 8.2.1.1. Type breakdown estimates & forecasts, 2019-2029
      • 8.2.1.2. End Use breakdown estimates & forecasts, 2019-2029
    • 8.2.2. Canada Cancer Gene Therapy Market
  • 8.3. Europe Cancer Gene Therapy Market Snapshot
    • 8.3.1. U.K. Cancer Gene Therapy Market
    • 8.3.2. Germany Cancer Gene Therapy Market
    • 8.3.3. France Cancer Gene Therapy Market
    • 8.3.4. Spain Cancer Gene Therapy Market
    • 8.3.5. Italy Cancer Gene Therapy Market
    • 8.3.6. Rest of Europe Cancer Gene Therapy Market
  • 8.4. Asia-Pacific Cancer Gene Therapy Market Snapshot
    • 8.4.1. China Cancer Gene Therapy Market
    • 8.4.2. India Cancer Gene Therapy Market
    • 8.4.3. Japan Cancer Gene Therapy Market
    • 8.4.4. Australia Cancer Gene Therapy Market
    • 8.4.5. South Korea Cancer Gene Therapy Market
    • 8.4.6. Rest of Asia Pacific Cancer Gene Therapy Market
  • 8.5. Latin America Cancer Gene Therapy Market Snapshot
    • 8.5.1. Brazil Cancer Gene Therapy Market
    • 8.5.2. Mexico Cancer Gene Therapy Market
  • 8.6. Rest of The World Cancer Gene Therapy Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Abeona Therapeutics Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Asklepios BioPharmaceutical Inc.
    • 9.2.3. Bluebird bio Inc.
    • 9.2.4. GlaxoSmithKlineInc.
    • 9.2.5. Introgen TherapeuticsInc.
    • 9.2.6. MerckKGaA
    • 9.2.7. BioCancell Inc.
    • 9.2.8. Elevate BioInc.
    • 9.2.9. Genelux Corporation
    • 9.2.10. OncoGenex Pharmaceuticals Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Cancer Gene Therapy Market, report scope
  • TABLE 2. Global Cancer Gene Therapy Market estimates & forecasts by Region 2019-2029 (USD Billion)
  • TABLE 3. Global Cancer Gene Therapy Market estimates & forecasts by Type 2019-2029 (USD Billion)
  • TABLE 4. Global Cancer Gene Therapy Market estimates & forecasts by End Use 2019-2029 (USD Billion)
  • TABLE 5. Global Cancer Gene Therapy Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 6. Global Cancer Gene Therapy Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 7. Global Cancer Gene Therapy Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 8. Global Cancer Gene Therapy Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 9. Global Cancer Gene Therapy Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 10. Global Cancer Gene Therapy Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 11. Global Cancer Gene Therapy Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 12. Global Cancer Gene Therapy Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 13. Global Cancer Gene Therapy Market by segment, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 14. Global Cancer Gene Therapy Market by region, estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 15. U.S. Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 16. U.S. Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 17. U.S. Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 18. Canada Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 19. Canada Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 20. Canada Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 21. UK Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 22. UK Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 23. UK Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 24. Germany Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 25. Germany Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 26. Germany Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 27. France Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 28. France Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 29. France Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 30. Italy Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 31. Italy Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 32. Italy Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 33. Spain Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 34. Spain Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 35. Spain Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 36. RoE Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 37. RoE Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 38. RoE Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 39. China Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 40. China Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 41. China Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 42. India Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 43. India Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 44. India Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 45. Japan Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 46. Japan Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 47. Japan Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 48. South Korea Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 49. South Korea Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 50. South Korea Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 51. Australia Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 52. Australia Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 53. Australia Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 54. RoAPAC Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 55. RoAPAC Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 56. RoAPAC Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 57. Brazil Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 58. Brazil Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 59. Brazil Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 60. Mexico Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 61. Mexico Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 62. Mexico Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 63. RoLA Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 64. RoLA Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 65. RoLA Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 66. Row Cancer Gene Therapy Market estimates & forecasts, 2019-2029 (USD Billion)
  • TABLE 67. Row Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 68. Row Cancer Gene Therapy Market estimates & forecasts by segment 2019-2029 (USD Billion)
  • TABLE 69. List of secondary sources, used in the study of global Cancer Gene Therapy Market
  • TABLE 70. List of primary sources, used in the study of global Cancer Gene Therapy Market
  • TABLE 71. Years considered for the study
  • TABLE 72. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Cancer Gene Therapy Market, research methodology
  • FIG 2. Global Cancer Gene Therapy Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Cancer Gene Therapy Market, key trends 2021
  • FIG 5. Global Cancer Gene Therapy Market, growth prospects 2022-2029
  • FIG 6. Global Cancer Gene Therapy Market, porters 5 force model
  • FIG 7. Global Cancer Gene Therapy Market, pest analysis
  • FIG 8. Global Cancer Gene Therapy Market, value chain analysis
  • FIG 9. Global Cancer Gene Therapy Market by segment, 2019 & 2029 (USD Billion)
  • FIG 10. Global Cancer Gene Therapy Market by segment, 2019 & 2029 (USD Billion)
  • FIG 11. Global Cancer Gene Therapy Market by segment, 2019 & 2029 (USD Billion)
  • FIG 12. Global Cancer Gene Therapy Market by segment, 2019 & 2029 (USD Billion)
  • FIG 13. Global Cancer Gene Therapy Market by segment, 2019 & 2029 (USD Billion)
  • FIG 14. Global Cancer Gene Therapy Market, regional snapshot 2019 & 2029
  • FIG 15. North America Cancer Gene Therapy Market 2019 & 2029 (USD Billion)
  • FIG 16. Europe Cancer Gene Therapy Market 2019 & 2029 (USD Billion)
  • FIG 17. Asia pacific Cancer Gene Therapy Market 2019 & 2029 (USD Billion)
  • FIG 18. Latin America Cancer Gene Therapy Market 2019 & 2029 (USD Billion)
  • FIG 19. Global Cancer Gene Therapy Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable